A Study to Assess Relatlimab and Nivolumab Fixed-dose Combination in Chinese Participants With Advanced Solid Tumors
Advanced Solid Tumors
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Sep 2025, none posted yet
Counts until it's fixed
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 24 (final count)
- Started
- Nov 30, 2021
- Main results expected
- Sep 1, 2025
- Fully finished
- Oct 24, 2025
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Adverse Events (AEs)
Measured over: Approximately 3 years
Number of Participants with Immune-mediated Adverse Events (IMAEs)
Measured over: Approximately 3 years
Number of Participants with Serious Adverse Events (SAEs)
Measured over: Approximately 3 years
Number of Deaths
Measured over: Approximately 3 years
Number of Participants with AEs Leading to Discontinuation
Measured over: Approximately 3 years
Number of Participants with Laboratory Abnormalities
Measured over: Approximately 3 years
Maximum Observed Plasma Concentration (Cmax) of Relatlimab
Measured over: Approximately 3 years
Time of Maximum Observed Plasma Concentration (Tmax) of Relatlimab
Measured over: Approximately 3 years
Trough Observed Plasma Concentration (Ctrough) of Relatlimab
Measured over: Approximately 3 years
Concentration of Relatlimab at the end of a dosing interval (Ctau)
Measured over: Approximately 3 years
Average concentration of Relatlimab over a dosing interval (Cavg(TAU))
Measured over: Approximately 3 years
Area under the concentration-time curve in one dosing interval (AUC(TAU)) of Relatlimab
Measured over: Approximately 3 years
Changes Tremor has spotted
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-09-01, no fading
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05134948 · record last updated 2025-12-03 · checked 2026-11-09 15:47 UTC